Several Interesting Reports on GBS and Sepsis In doing

New Post Public Reply Private Reply Replies (1) Message Board
Machiavelli10

Several Interesting Reports on GBS and Sepsis

In doing some background work as I think through some specific economic implications of the N-Assay technology I looked at some information that people on this site might like to view. It helped me better understand the N-Assay potential as well as its medical importance. So I am sharing it with you as a matter of general interest.

Sepsis: use of clinical criteria as well as novel diagnostic tests aim to improve patient outcomes

www.healthgrades.com/physician/dr-jonathan-faro-gdfp2/patient-ratings#QualitySurveyResults_anchor

By Jonathan Faro, MD, April 2014


Sepsis, as defined by Stedman’s Medical Dictionary, is “the presence of various pathogenic organisms, or their toxins, in the blood or tissues.”1 …

When a clinician is confronted with a patient who is possibly septic, multiple criteria and diagnostic tests are used to reach this diagnosis. As the clinical picture may shift rapidly, bringing about sudden decompensation of the patient, the clinician must be prepared to act even before the results of ordered tests are available. This empiric treatment is then adjusted accordingly based on both the patient’s response and the data as it is obtained. Here, we review findings common with sepsis, and the diagnostics that allow us to tailor the treatment and allow for the best possible outcome….

Regardless of the degree of sepsis, at least two or more of the following are required to make the diagnosis: fever, tachycardia, tachypnea, and leukocytosis. Sepsis is notably more severe when it is accompanied by organ dysfunction due to hypotension, which leads to hypoperfusion of organs. This end-organ injury may be made apparent as decreased urine output, altered mental status, or lactic acidosis, and in its more severe state, is associated with multiple organ failure (multiple organ dysfunction syndrome).

With more than 750,000 cases of sepsis occurring annually, and more than 200,000 deaths each year attributable to sepsis, it is important that this condition is promptly recognized.5 An inadequate approach to working up a septic patient may range from the clinician failing to recognize when infection is present, to administering inappropriate empiric antibiotics, to performing an inadequate examination, and even to sending off incorrect laboratory tests or failing to order the correct tests, such as gram stain/culture, which will aid in targeting empiric treatment choices. Equally serious and potentially devastating is the failure to perform surgical intervention in a timely manner when required for adequate treatment.

Once a differential has been narrowed down to an infectious agent as the underlying cause for the patient’s presenting condition, an appropriate antibiotic may be selected based on a few generalities. In obstetrical or gynecological patients, for example, the anatomic location of the infection and the time of onset to recognition of the infection both play important roles. For abdominal incisions, e.g., following cesarean delivery or hysterectomy, gram-positive organisms such as staph aureus and strep pyogenes as well as streptococcus agalactiae are important to consider, along with gram-negative facultative anaerobes. We have seen in our institution an increase in the number of post-operative wounds infected with methicillin-resistant staphylococcus aureus (MRSA), and it is important to include coverage against this organism. It should also be noted that the importance of obtaining culture and gram stain of infected tissue prior to the initiation of empiric treatment cannot be overemphasized.6

Equally important in determining when sepsis is present and its resolution or response to treatment is the rapid identification of the specific pathogen(s) present and their susceptibility to clinically relevant antimicrobials. While gram stain of infected fluid/tissue may be done rapidly and may allow for categorization of a suspected infectious agent, culture and then follow-up determination of antimicrobial resistance may take several days. Recently, the Infectious Diseases Society of America (IDSA) has led a strong push to foster the development of new diagnostic tests that will be easy to use and provide results within an hour.10

Caliendo et al. state that the ideal diagnostic test is accurate; relies on heat-stable reagents with an extended shelf-life; is easily portable; requires minimal technical skills; is rapid (<1 hr), sensitive, and specific; does not require being run in large batches; is cost-effective; and is suitable for use in a broad range of clinical samples. They say that currently PCR-based tests meet some but not all of these criteria.10

In work that my colleagues and I at the University of Texas Health Sciences Center have done on group B streptococcus (GBS), we have developed an antibody-based test (termed the N-Assay) which allows for the simultaneous identification of a microbial pathogen and determination of its antimicrobial susceptibility. By substituting antibodies specific for varying pathogens, one may selectively identify pathogens present in a patient. A similar assay that we developed in 2010 was tested earlier this year in more than 300 patients, and it was found that GBS could be reliably detected in much less time than is typically required for culture.11

We have converted this test to an ELISA format, and as such, have seen preliminary results that allow for identification of GBS in under an hour. Furthermore, by changing the specificity of the capture antibody, we are able to detect vancomycin-resistant enterococcus (VRE), Neisseria gonorrhea, and E.coli, as well as Candida albicans.

Initial results with VRE have consistently shown that susceptibility to selected antibiotics may be reliably determined after a brief period of culture.

Every effort must be made to stem the development of sepsis. More rapid diagnostic tests will play an increasingly important role in aiding the clinician not only in making the diagnosis, but in tailoring the course of treatment. In addition to improved tests, the clinician will continue to play a central role in determining whether the course of action requires aggressive resuscitation and broad spectrum antibiotics, as well as operative management and aggressive debridement.

Who May Be Affected by Group B Strep?

www.groupbstrep.org/resources/pamphlet.pdf


15,000 to 18,000 newborns and adults in the United States will contract serious GBS disease each year, resulting in bloodstream, respiratory, and other devastating infections. About half of all GBS disease occurs in newborns and is acquired during childbirth when a baby comes into direct contact with the bacteria carried by the mother. GBS causes infections in pregnant women - in the womb, in amniotic fluid, in incisions following cesarean sections, and in the urinary tract. Each year there are over 50,000 cases of such infections in pregnant women. 35-40% of GBS disease occurs in the elderly or in adults with chronic medical conditions.

Approximately 8,000 babies in the United States contract serious GBS disease each year. Up to 800 of these babies may die from it, and up to 20% of the babies who survive GBS-related meningitis are left permanently handicapped. GBS disease is more common than other, better known, newborn problems such as rubella, congenital syphilis, and spina bifida. Some babies that survive, especially those who develop meningitis, may develop long-term medical problems, including hearing or vision loss, varying degrees of physical and learning disabilities, and cerebral palsy.


Birthwise Group

www.birthwisemc.com/group-b-strep.html


Group B Strep (GBS) infection is the leading cause of illness and death among infants in the United States. Current prevention guidelines have reduced the number of babies who get sick from 8000 per year to 1200 per year. Between 10-30% of women carry this bacterium in their vagina or rectum at the time of birth. The bacteria is generally passed from mother to baby during birth during labor or after the membranes rupture although it can happen through intact membranes. ... If certain risk factors are present, the baby is much more likely to get sick. ________________________________________

Additional risk factors:
Membrane rupture >12 hours (6%)
Preterm birth (3-50%)
Fever during labor (15%)
Previous baby with GBS disease (10%)
GBS positive urine culture this pregnancy (4%)

If these factors are present, they mean that the baby is more likely than the 1-2% to get sick. The increased percentage is indicated in the parentheses.
________________________________________

Most cases (70%) occur in babies born at term. The most common clinical symptom is respiratory distress along with other signs of infection beginning within 24-48 hours of birth. Pneumonia and sepsis (blood infection) are most common but meningitis can also occur.

New Approaches to Preventing, Diagnosing, and Treating Neonatal Sepsis

• Karen Edmond mail,
• Anita Zaidi
• Published: March 09, 2010
• DOI: 10.1371/journal.pmed.1000213


Neonatal sepsis or septicaemia is a clinical syndrome characterized by systemic signs of circulatory compromise (e.g., poor peripheral perfusion, pallor, hypotonia, poor responsiveness) caused by invasion of the bloodstream by bacteria in the first month of life. In the pre-antibiotic era neonatal sepsis was usually fatal. Case fatality rates in antibiotic treated infants now range between 5% and 60% with the highest rates reported from the lowest-income countries [1].

The World Health Organization (WHO) estimates that 1 million deaths per year (10% of all under-five mortality) are due to neonatal sepsis and that 42% of these deaths occur in the first week of life [2]. There are wide disparities in neonatal care between high- and low-income countries. In high-income countries the major concern is the increasing numbers of extremely premature infants with high nosocomial infection rates due to multiresistant organisms in intensive care units. Health facility infections are also a major problem in low-income countries, but the more pressing issues are the high proportion of home deliveries in unclean environments predisposing to sepsis and ensuring that all neonates have access to effective interventions from health care providers in the first days of life2.

Indeed, new strategies that can prevent, diagnose, and treat neonates with sepsis are needed in both low- and high-income settings.

Pathogenesis of Neonatal Infections

• Distal risk factors for neonatal sepsis include poverty and poor environmental conditions. Proximate factors include prolonged rupture of membranes, preterm labour, maternal pyrexia, unhygienic intrapartum and postnatal care, low birth weight, and prelacteal feeding of contaminated foods and fluids [3]–[5].

The bacteria that cause neonatal sepsis are acquired shortly before, during, and after delivery (Figure 1). They can be obtained directly from mother's blood, skin, or vaginal tract before or during delivery or from the environment during and after delivery. Streptococcus agalactiae (Group B streptococcus, GBS) is the most common cause of neonatal sepsis in many countries, ...





Nanologix Inc (NNLX) Stock Research Links

NNLX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Global Movement Urges Dr. Hak Ja Han's Release

Updated Category News Views 4

Under the shadows of Manhattan's skyline, something more than a regular service took shape. The New Yorker Hotel hosted an impassioned gathering of the Family Federation for World Peace and Unification. These folks weren't just saying their prayers; they were making a call—loud and resonant—for the release of Dr. Hak Ja Han. The Power of Collective Voices Gathering in...

Continue Reading
Automotive ECU Market Aims $160B by 2033

Updated Category News Views 0

Automotive ECUs Under the Spotlight Picture this: By 2033, the automotive ECU market is expected to balloon to a whopping $160.59 billion. That's some serious cash, and it ain't just pocket change. This $47 billion jump from 2026 isn't just happening by accident—it's got everything to do with high-octane changes in the industry. With a 5.1% CAGR, you best believe it's a...

Continue Reading
Rznomics Unveils Breakthrough in Circular RNA Production

Updated Category News Views 1

Decoding the RNA Revolution Ever heard of circular RNA (circRNA)? This ain't your typical strand of genetic code. Unlike their straight-laced, linear counterparts, these RNAs form a loop you can't just break. Picture them as the Kevlar vests of the RNA world—tough, resilient, and packing the promise of next-gen treatments in their covalent loops. Here we’ve got...

Continue Reading
BYD's Chip Mastery Amid China's Auto Supply Tensions

Updated Category News Views 2

Chips, the New Battleground in Automotive Innovation Here we are, folks, knee-deep in a tech-driven car revolution where semiconductors aren't just the icing on the cake—they're the cake itself. As vehicles morph into veritable computers on wheels, reliance on chips is hitting a fever pitch. FYI, it's not just about making cars go; we're talking power management,...

Continue Reading
York Space Systems Faces Class Action Over Misleading IPO

Updated Category News Views 3

York Space Systems Under the Legal Spotlight Ever get that feeling when something just doesn’t sit right? Like a burr under the saddle, York Space Systems is now grappling with a class action lawsuit that's throwing a heap of shade on its recent moves. What’s at play? Bronstein, Gewirtz & Grossman, LLC, a law firm that seems to have a nose for corporate messes, has...

Continue Reading
MERACH Unveils W60 Plus: A Game Changer for Home Fitness

Updated Category News Views 2

MERACH's Ambitious Leap into European Markets Walking is one of life's simple pleasures, but it's not always convenient in our work-from-home driven world. That's where MERACH's UltraWalk W60 Plus comes in, dropping anchor in Europe like a brand new ship with all the bells and whistles. What makes this walking pad different, you ask? It's designed to become a natural...

Continue Reading
Clover's RSV Combo Vaccine Shows Promise in Trials

Updated Category News Views 5

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

Continue Reading
53% of European Telecom Users Eye Provider Switch

Updated Category News Views 3

Change Is Brewing in Europe's Telecom Markets Seems like Europe's telco scene is simmering. Over half of consumers in major European markets are giving their mobile providers the side-eye, ready to jump ship. That's putting the heat on operators who once banked on loyalty programs to keep their customer base intact. Diverse Loyalty Challenges Across Europe What's...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 6

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading
KuCoin's KCUSD Tackles Stablecoin Idle Capital Problem

Updated Category News Views 0

KuCoin's Bold Move with KCUSD Folks, the cat's outta the bag with KuCoin's latest maneuver—introducing KCUSD. At first glance, it seems like they're just introducing another fancy stablecoin product, but peel the onion and there's more to it. We're talking about shaking up how stablecoins sit tight doing nada in the crypto world. KCUSD is out to make those idle balances...

Continue Reading

Top 5 Most Recently Viewed Articles

STMicroelectronics Leadership Changes As Company Faces Challenges

Updated Category News Views 277

Leadership Changes at STMicroelectronics Italy is contemplating a significant shift in leadership at STMicroelectronics as concerns about the company's direction and performance have surfaced. The Italian government is mulling over the possibility of replacing CEO Jean-Marc Chéry in light of perceived inadequate results, especially as the semiconductor industry continues...

Continue Reading
Empowering Young Minds with Tricoci University’s New Beauty Program

Updated Category News Views 397

Introducing Tricoci Forward: A New Initiative for Aspiring Beauticians Tricoci University of Beauty Culture is thrilled to unveil Tricoci Forward, a groundbreaking program aimed at inspiring high school students interested in the beauty industry. This initiative not only welcomes budding talents but also cultivates an environment where creativity and ambition can...

Continue Reading
Enhancements in ezPaycheck to Meet New Tax Regulations

Updated Category News Views 108

New Features in ezPaycheck for Enhanced Compliance The recent updates in ezPaycheck are here to support businesses in adapting to the changing landscape of tax regulations following the enactment of The One Big Beautiful Bill. This update comes as a critical resource that empowers small and mid-sized businesses, accountants, and payroll processors to remain compliant with...

Continue Reading
Unicycive Therapeutics: Upcoming Investor Conferences Insights

Updated Category News Views 191

Unicycive Therapeutics and Their Upcoming Appearances Unicycive Therapeutics, Inc., a pioneering clinical-stage biotechnology company dedicated to developing innovative therapies for kidney disease, is poised to make a significant impact at two upcoming investment conferences. The company's Chief Executive Officer, Shalabh Gupta, M.D., will engage with investors, sharing...

Continue Reading
Unlocking the Potential of Algae: A Sustainable Nutritional Shift

Updated Category News Views 119

The Surging Algae Products Market: A Sustainable Alternative The algae products market is experiencing remarkable growth, showcasing its potential to transform nutrition and wellness. Originally considered a niche, algae have emerged as a key player in food, health, beauty, and pharmaceuticals. With a valuation projected to rise significantly, the market is anticipated to...

Continue Reading